SRSF2 enhances anti-tumor immune responses by affecting H3K27Ac levels of related genes and the recruitment of STAT3, providing a new idea for reversing the depletion of TILs (Wang Z. et al., 2020). This evidence concerns the gene SRSF2 and neoplasm.